Background: Hyperlipidemia is one of the most common causes of atherosclerosis. Secondary hyperlipidemia could be due to obesity, diabetes mellitus, alcohol consumption, kidney failure, nephrotic syndrome, etc. It does not cause any symptoms and may go unnoticed for years. Dietary modifications along with medications are the mainstay of treatment in moderate to severe causes of hyperlipidemia. Statins are one of the most widely used drugs for the treatment of this disorder. Myopathy and persistent liver enzyme abnormalities are the most deleterious adverse effects of statins. The use of phytochemicals would minimize the adverse effects encountered with statins. In the present study, we studied and compared the hypolipidemic effect of Curcuma longa Linn. with atorvastatin in obese hyperlipidemic rats.
Aims and Objectives: The present study was done to evaluate the hypolipidemic effect of turmeric (C. longa Linn.) and to compare it with atorvastatin in albino rats.
Materials and Methods: Wistar albino rats weighing 120Ė150 g were utilized for the present study. The ethanolic extract of C. longa Linn. was administered orally to obese rats for 8 weeks. Serial estimation of lipid profile was done at 2, 4, 6, and 8 weeks, respectively. Lipid profile was assessed using serum cholesterol, serum high-density lipoproteins (HDLs), serum low-density lipoproteins (LDLs), and serum triglycerides (TGs) as parameters.
Results: Statistically significant improvement in lipid profile (P < 0.05) was seen after administration of C. longa in obese rats. There was significant reduction in serum cholesterol, serum LDL, and serum TGs. However, serum HDL did not show a significant increase.
Conclusion: C. longa Linn. had a hypolipidemic effect.
Hyperlipidemia; Myopathy; Statins
Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy.
Ho P, Zheng JQ, Wu CC, Hou YC, Liu WC, Lu CL, Zheng CM, Lu KC, Chao YC
International journal of medical sciences. 2021; 18(2): 314-324
Statins and lower mortality in rheumatic diseases: An effect of immortal time bias?
Abrahami D, Hudson M, Suissa S
Seminars in arthritis and rheumatism. 2021; 51(1): 211-218
Whole-exome analyses of congenital muscular dystrophy and congenital myopathy patients from India reveal a wide spectrum of known and novel mutations.
Sanga S, Ghosh A, Kumar K, Polavarapu K, Preethish-Kumar V, Vengalil S, Nashi S, Bardhan M, Arunachal G, Raju S, Gayathri N, Biswas NK, Chakrabarti S, Nalini A, Roy S, Acharya M
European journal of neurology. 2021; 28(3): 992-1003
Treatment of Hyperlipidemia Induced in Rats by Sweet Almond (S.A.) Watery Extract (Prunus Amygdalus) and Compares with Atorvastatin
Mohammad S. Jadaan, Atheer A. Khashan, Omar Salim Ibrahim
Systematic Reviews in Pharmacy. 2021; 12(1): 1050-1052
Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study.
Ha J, Lee B, Park JM, Kang M, Oh J, Lee CJ, Park S, Kang SM, Lee SH
Scientific reports. 2021; 11(1): 8884
Effects of statins on mitochondrial pathways.
Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, von Haehling S, Jamialahmadi T, Sahebkar A
Journal of cachexia, sarcopenia and muscle. 2021; ():
Mediterranean Diet and Physical Activity Decrease the Initiation of Cardiovascular Drug Use in High Cardiovascular Risk Individuals: A Cohort Study.
Rib√≥-Coll M, Castro-Barquero S, Lassale C, Sacanella E, Ros E, Toledo E, Sorl√≠ JV, D√≠az-L√≥pez A, Lapetra J, Mu√Īoz-Bravo C, Ar√≥s F, Fiol M, Serra-Majem L, Pinto X, Casta√Īer O, Fern√°ndez-L√°zaro CI, Portol√©s O, Babio N, Estruch R, Hern√°ez √Ā
Antioxidants (Basel, Switzerland). 2021; 10(3):
Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs.
Joharatnam-Hogan N, Alexandre L, Yarmolinsky J, Lake B, Capps N, Martin RM, Ring A, Cafferty F, Langley RE
Current oncology reports. 2021; 23(3): 29